The USP15 biological thermostat: A promising novel therapeutic target in cancer
USP15 as a "Biological Thermostat" at the core of a TGFβ chain reactio
Dr. Seoane's team has unmasked the USP15 enzyme as activator of the TGFβ chain reaction. In tumors the USP15-TGFß axis is deregulated due to USP15 gene amplification leading to an aberrant TGFß activation.
USP15 acts by controlling and correcting the TGFβ activity in the same way that a thermostat regulates temperature. If the TGFβ activity is high, it reduces; and if it is low, it increases the TGFβ activity. USP15 therefore achieves optimal TGFβ activity.
Protein stability is regulated through the elimination or aggregation of ubiquitins, small proteins that establish which molecules need to be eliminated. This process is finely regulated by deubiquitinating enzymes (DUBs) such as USP15 which determine the correct level of a protein under certain physiological conditions. In this orchestrated manner, USP15 controls and adapts the TGFβ receptor stability and, therefore, the activity of the pathway.
The problem arises when, in some tumors, the USP15 gene is amplified due to genetic mutations and the enzyme is over produced. The thermostat breaks down and is therefore only sensing the "cold" resulting in the overactivation of the TGFβ pathway. Remarkably, this is not only a phenomenum of glioblastomas since the USP15 gene has also been found activated in other types of cancer such as breast or ovarian cancer.
Dr. Joan Seoane explained "When we inhibited USP15 in a real model of human glioblastoma, TGFβ activity decreased and the tumor did not develop. USP15 regulates tumor progression and is critical in cancer."
DUBs (deubiquitinating enzymes): a novel avenue in therapeutic targets
Sometimes potentially powerful therapeutic targets are found but are not pharmacologically accessible due to their biochemical characteristics. "Enzymes in general - particularly deubiquitinating enzymes (DUBs) such as USP15, can easily be deactivated and are therefore good therapeutic targets", Seoane commented, "our results, generated thanks to the funding received from the Spanish Association Against Cancer (AECC), show exciting new promise in improved treatment of cancer patients.".
Most read news
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.